Table 2.

NK-MC Product Characteristics at Release (Minnesota) and Pre-infusion (Boston)

Patient	MC/kg Dose Level	CD56+/CD3− (%)	CD3+ (%)	Viability (%) Post wash
		Minnesota		Boston
1	105	26	0.6	98
2	105	28	0.8	93
3	105	11*	0.43	99
4	106	23	0.1	94
5	106	20	0.08	99
6	106	35	0.15	95
7	106	42	0.06	95
8	107	24	0.08	95
9	107	19	0.16	93
10	107	26	0.12	92
11	2 × 107	33	0.08	94
12	2 × 107	37	0.16	96
13	2 × 107	20	1.83	85
Median		26	0.15	95
Range		11–42	0.06–1..83	85–99

^*Product delayed 8 hours due to product misplacement by courier (AirNet).